OFFICIAL ENTIS POSITION STATEMENT: Paracetamol (acetaminophen, APAP) use in pregnancy

A recent “consensus statement” review article published in Nature Reviews Endocrinology concluded that there is a growing body of evidence supporting the hypothesis that in utero exposure to paracetamol (or acetaminophen, APAP) impacts fetal development. This paper has been widely cited by national media organisations, some of which reported the findings in an alarming manner. ENTIS holds the position that […]

» Read more

Save The Date: 10th November 2021 – Virtual ENTIS Business Meeting

The ENTIS Board are pleased to announce this year’s ENTIS business meeting will be held virtually on 10th November 2021, and will run from 13:30 to 16:30 Central European Time (CET). Details including the agenda and online access instructions will be posted in the members’ only section of the ENTIS website shortly.  The agenda will include an update from each TIS, a case report […]

» Read more

ENTIS challenge to the EMA PRAC recommendations on ondansetron use in pregnancy

In July 2019, the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) released an updated, comprehensive assessment report on the use of ondansetron in the first trimester. The ensuing Summary of Product Characteristics (SmPC) was updated in November 2019 with important changes to section on “Fertility, pregnancy and lactation.” The SmPC now states that ondansetron should not be used […]

» Read more

ENTIS Position Statement; COVID-19 vaccines in pregnancy and lactation

The ENTIS Board and Scientific Committee are pleased to announce the official position of the ENTIS organisation on the use of COVID-19 vaccines in pregnant and lactating women. In summary, ENTIS holds the position that vaccination is the currently the most effective measure to reduce the risks associated with COVID-19 disease in pregnant women. Current safety data are reassuring, and […]

» Read more

New members of the ENTIS Scientific Committee

The ENTIS Board and Scientific Committee are happy to announce that Professor Per Damkier (MD, PhD) has been elected as the new chair of the ENTIS Scientific Committee. The Board and Scientific Committee are also pleased to announce that two new members will be joining the committee to replace two retiring members (Professor Hedvig Nordeng and Dr Yusuf Cem Kaplan, […]

» Read more

Save the Date: Virtual Scientific Meeting – Tuesday 20th April and 27th May

The ENTIS Board and  Scientific Committee are pleased to announce the 2021 Scientific Meeting which will take place virtually on two dates in April and May. Please mark your diaries with the following dates and times: Tuesday 20th April 16:00-18:00 CEST Thursday 27th May 16:00-18:00 CEST These online events will include oral presentations along with plenary sessions about COVID-19 vaccination in pregnancy […]

» Read more

Pregnant and breastfeeding women’s mental health status during the first wave of the COVID-19 pandemic

Collaborators from ENTIS and affiliated organisations have published the results of a web-based survey investigating how the first wave of the COVID-19 pandemic impacted the mental health status of pregnant and breastfeeding women. This multinational survey was promoted in Ireland, Norway, Switzerland, the Netherlands, and the UK between 16 June and 14 July 2020, and identified high levels of depressive […]

» Read more

Should ondansetron be avoided in pregnancy?

Two short debate papers have been published in the British Journal of Obstetrics and Gynaecology discussing the safety of ondansetron use in early pregnancy. Professor Per Damkier in collaboration with the ENTIS Scientific Committee led the argument against avoiding ondansetron use in pregnancy, while Professor Russell Kirby from the College of Public Health, University of South Florida led the argument […]

» Read more
1 2 3 4